The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.
ConditionCancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBaylor Research Institute
About this trial
The purpose of the Texas Immuno-Oncology Biorepository (TIOB) is to collect and store well-defined and well-annotated serial biospecimens of tissue, blood, urine and stool in a longitudinal manner from cancer patients who are receiving either standard of care surgical interventions and or FDA approved immunotherapeutics across the largest not-for-profit health system in Texas. Comprehensive clinical and radiological data from a diverse population of patients with different racial, social and ethnic backgrounds matched with serial biospecimens over a patients journey with cancer marks the TIOB as a unique research facility.
Eligibility criteria
Qualifiers
Participant is over 18 years of age at the time of signing the informed consent form.
Participant is able and willing to sign an informed consent form.
Participant is suspected by a provider of being at risk for developing cancer,
Participants who may be candidates for or are scheduled to receive standard of care immunotherapy treatment for the first time for their current cancer diagnosis, regardless of any prior non-immunotherapy treatment.
Disqualifiers
Participant is unable or unwilling to donate blood.
Concurrent medical or psychiatric condition or disease that may compromise the ability to give documented informed consent, is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
10,000 Participants
are grouped into 2 trial groupsSponsors and collaborators
Baylor Research Institute
Lead sponsor
Translational Genomics Research Institute
Collaborator
Source ClinicalTrials.gov